Health Technology Takeda Pharmaceutical Co., Ltd. Business Summary
Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products. The Consumer Healthcare segment includes the manufacture and sale of OTC drugs and quasi-drugs. The Other segment includes manufacture and sale of reagents, clinical diagnostics, and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.
Financial Highlights
Mar 2023
JPY USD Revenue 4,027.47B 29,719.25M Gross Profit 2,240.96B 16,536.34M Operating income 610,329M 4,503.69M Income before tax 383,720M 2,831.51M Net income 317,017M 2,339.30M EBITDA 1,274.72B 9,406.38M Diluted EPS 201.93 1.49 Dividends Per Share 180 1.32 Total Assets 13,957.75B 104,874.52M Total liabilities 7,603.08B 57,127.35M Total equity 6,354.12B 47,743.04M Operating cash flow 877,217M 6,473.09M Currency in JPY Currency in USD
Historical Data Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Revenue
2,097.22B
3,291.18B
3,197.81B
3,569.00B
4,027.47B
Gross Profit
1,275.55B
1,789.37B
1,798.37B
2,043.63B
2,240.96B
Operating income
218,686M
302,612M
447,610M
610,496M
610,329M
Income before tax
127,612M
-60,754M
366,159M
317,938M
383,720M
Net income
135,192M
44,241M
376,005M
230,059M
317,017M
EBITDA
466,377M
886,261M
1,007.28B
1,193.64B
1,274.72B
Diluted EPS
139.82
28.24
238.95
145.86
201.93
Dividends Per Share
180
180
180
180
180
Total Assets
13,792.77B
12,821.09B
12,912.29B
13,178.01B
13,957.75B
Total liabilities
8,606.78B
8,093.60B
7,735.11B
7,494.49B
7,603.08B
Total equity
5,181.98B
4,723.48B
5,173.03B
5,683.01B
6,354.12B
Operating cash flow
302,609M
555,410M
905,073M
1,021.21B
877,217M
Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Revenue
18,911.85M
30,270.54M
30,151.70M
31,760.44M
29,719.25M
Gross Profit
11,502.42M
16,457.72M
16,956.61M
18,186.20M
16,536.34M
Operating income
1,972.01M
2,783.25M
4,220.44M
5,432.77M
4,503.69M
Income before tax
1,150.74M
-558.78M
3,452.46M
2,829.31M
2,831.51M
Net income
1,219.10M
406.90M
3,545.29M
2,047.28M
2,339.30M
EBITDA
4,205.58M
8,151.34M
9,497.50M
10,622.21M
9,406.38M
Diluted EPS
1.26
0.25
2.25
1.29
1.49
Dividends Per Share
1.62
1.65
1.69
1.60
1.32
Total Assets
124,612.85M
118,763.31M
116,853.33M
108,572.75M
104,874.52M
Total liabilities
77,759.25M
74,972.05M
70,001.05M
61,746.62M
57,127.35M
Total equity
46,817.41M
43,754.18M
46,814.81M
46,821.99M
47,743.04M
Operating cash flow
2,728.79M
5,108.35M
8,533.80M
9,087.77M
6,473.09M
Valuation Measures
Mar 2023
PER 21.29 ROA 2.33% ROE 5.26% Operating margin 15.15% Profit margin 7.87%
Key executives
President, CEO & Representative Director:
Christophe Weber
Chief Financial Officer & Director:
Constantine Saroukos
Director, President-Research & Development:
Andrew S. Plump
Chief Medical & Scientific Officer:
Michael E. Mendelsohn
Chief Accounting Officer & Corporate Controller:
Norimasa Takeda Shareholders
Nomura Asset Management Co., Ltd. (4.2%)
Sumitomo Mitsui Trust Asset Management Co., Ltd. (3.8%)
The Vanguard Group, Inc. (2.5%)
Nikko Asset Management Co., Ltd. (2.0%)
Daiwa Asset Management Co. Ltd. (1.9%)
BlackRock Fund Advisors (1.8%)
Nippon Life Insurance Co. (1.8%)
Capital Research & Management Co. (Global Investors) (1.6%)
Norges Bank Investment Management (1.5%)
Capital International Ltd. (1.3%)
Related Companies
Takeda Pharmaceutical Co Ltd /Asker Pharma Manufacturing Ops/
Nimbus Lakshmi, Inc.
Takeda Digital Ventures
Takeda Pharmaceutical Employee Long Term Incentive Plan
Takeda Dunboyne Biologics Ltd.
Plasmaspendedienst GmbH
Takeda Belgium NV
Takeda Pharmaceutical Co. Ltd. /Non Core Assets/
Adaptate Biotherapeutics Ltd.
Takeda Re Insurance AG
Plasmapunkt Favoriten GmbH
Takeda Malaysia Sdn. Bhd.
Takeda Pharmaceutical Co. Ltd. /Latam Bus/
Takeda Oranienburg Real Estate GmbH & Co. KG
Pvp Biologics, Inc.
Maverick Therapeutics, Inc.
Gammadelta Therapeutics Ltd.
Takeda Pharmaceutical Director Incentive Plan
Takeda Pharmaceutical Employee Incentive Plan
Oy Leiras Takeda Pharmaceuticals AB
Takeda Architectural Design Consulting (Shanghai) Co. Ltd.
Takeda Pharma AB
Takeda Development Center Americas, Inc.
Takeda Ukraine LLC
Takeda Pharmaceuticals Taiwan Ltd.
Takeda SRL
Takeda Hellas SA
Takeda Christiaens SCA/CVA
Takeda Belgium SCA/CVA
Takeda Vaccines Pte Ltd.
Competitors
AstraZeneca PLC
Grifols, S.A. Class A
Green Cross Corporation
Amgen Inc.
CSL Limited
Novo Nordisk A/S Class B
Amicus Therapeutics, Inc.
Pharming Group NV
Protalix Biotherapeutics, Inc.
ADMA Biologics, Inc.
Novartis AG
Pfizer Inc.
Johnson & Johnson
Sanofi
Mochida Pharmaceutical Co., Ltd.
AbbVie, Inc.
Bristol-Myers Squibb Company
Organon & Co.
Merck & Co., Inc.
Bayer AG
Roche Holding Ltd Dividend Right Cert.
Karyopharm Therapeutics, Inc.
Swedish Orphan Biovitrum AB
UCB S.A.
Merck KGaA
JCR Pharmaceuticals Co., Ltd.
Supernus Pharmaceuticals, Inc.
Oncopeptides AB
BioCryst Pharmaceuticals, Inc.
ISU Abxis Co., Ltd.
Copyright © 2023 FactSet Research Systems Inc. All rights reserved.
Last Updated on 26 May, 2023
Take your reading anywhere with offline reading functions Never miss a story with breaking news alerts Customize your reading experience
Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.
Celebrate our next chapter
Free access for everyone - Sep. 30
Find out more
By continuing to browse this website, you accept cookies which are used for several reasons such as personalizing content/ads and analyzing how this website is used. Please review our
Cookie Policy
to learn how you can update your cookie settings.
Accept & Continue
Close